Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Practical Updates in Adult-onset Mastocytosis, MCAS, and HAT for the Dermatologist

Description

The session focuses on practical updates regarding the classification of mastocytosis and broader mast cell disorders, featuring expert panelists who contributed to international classifications. The format begins with case presentations led by Dr. Lauren Madigan from the University of Utah, moving on to a recorded lecture from Dr. Mariana Castells, followed by discussions led by Dr. Hartman. The initial cases presented include various patients with differing symptoms and tryptase levels, prompting discussions on their likelihood of having systemic mastocytosis. Patients range from a man in his 30s with significant fatigue and gastrointestinal issues to a 19-year-old woman with early-onset symptoms and a markedly elevated tryptase level. Several cases explore nuances in diagnosis based on symptomatology and findings from skin biopsies, highlighting the importance of clinical morphology and history in evaluating systemic mastocytosis. The final case involves a younger man presenting with significant allergic responses and gastrointestinal complaints, with further discussion anticipated about diagnostic testing results. The session aims to bridge clinical practice with the latest in mastocytosis research, culminating in revisiting the cases discussed to clarify diagnostic and treatment strategies.

View more

Conclusions

  • Systemic mastocytosis is a concern for patients with elevated tryptase levels and significant symptomatic presentations.
  • Case studies presented highlight the variability in systemic mastocytosis symptoms and biopsy results among patients.
  • Patients with normal or low tryptase levels and no systemic symptoms may not have systemic mastocytosis despite previous diagnoses.
  • The age of onset and clinical history can influence the diagnosis and management of mastocytosis.
  • Further evaluation and testing, including KIT mutation analysis, are crucial in determining the presence of systemic mastocytosis.